Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.

• Type of Material: Article
• Authors: Pankit Vachhani, Roswell Park Cancer Institute; Jason H. Mendler, University of Rochester Medical Center; Andrew Evans, University of Rochester Medical Center; George Deeb, Emory University; Petr Starostik, University of Florida; Paul K. Wallace, Roswell Park Cancer Institute; Eunice S. Wang, Roswell Park Cancer Institute
• Language: English
• Date: 2016-12-29
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2016 Pankit Vachhani et al.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1155/2016/1259759
• Title of Journal or Parent Work: Case Reports in Hematology
• ISSN: 2090-6560
• Volume: 2016
• Research Categories: Health Sciences, Oncology; Health Sciences, Pathology

Abstract

Spontaneous remission (SR) of acute myeloid leukemia (AML) is a very rare phenomenon. AML characterized by FLT3 internal tandem duplication (FLT3 ITD) is typically associated with an aggressive clinical course with rapid progression, relapse, and short overall survival in the absence of transplantation. We report here the first case of SR of FLT3 ITD mutant AML in the literature. Our patient was an elderly woman with relapsed NPM1 and FLT3 ITD mutant AML whose disease underwent SR for a brief duration without precipitating cause. We review the potential immune mechanisms underlying SR in AML and discuss the implications for novel immunotherapeutic approaches for FLT3 mutant AML.